Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Source filing unavailable
Q3 2013 · —
Revenue$213.25M$213.25M+1.5% vs Q3 2012 Net Income-$30.33M-$30.33MN/M vs Q3 2012 EPS Diluted-$1.09-$1.09N/M vs Q3 2012 Gross Profit$131,479,000+0.7% Operating Income-$31,141,000N/M Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
$30,808,000
+10.4%
Free Cash Flowderived$17,561,000+114.4% Margins · derivedGross margin61.7%−0.5 pt vs Q3 2012
Operating margin-14.6%−24.0 pt vs Q3 2012
Net margin-14.2%−20.5 pt vs Q3 2012